Sobi Licenses Innate’s Skin-Lymphoma Drug in a Deal Worth Up to $580M

Swedish rare-disease company Sobi is licensing a cancer drug from France’s Innate Pharma in a deal worth up to $580 million, taking on commercialisation of a first-in-class treatment for a rare skin lymphoma.

Announced August 10, 2026, the agreement gives Innate $75 million up front, $40 million in near-term development milestones for its Sézary syndrome programme, and up to $465 million in later regulatory and commercial milestones, plus double-digit royalties.

What the disease is

Cutaneous T-cell lymphoma is a cancer of T cells that home to the skin, and the two subtypes named here differ meaningfully.

Mycosis fungoides is the more common form, typically indolent, beginning as patches or plaques that can be mistaken for eczema or psoriasis for years before diagnosis. Many patients live with it for decades.

Sézary syndrome is the aggressive leukaemic variant, in which malignant T cells circulate in the blood as well as infiltrating the skin. Patients develop widespread redness and scaling of the entire skin surface, intractable itching that is genuinely debilitating, and a poor prognosis. It is the subtype where treatment is most urgently needed and options are fewest.

The target

Lacutamab is a first-in-class antibody targeting KIR3DL2, a receptor on the cancer cells.

The target is well chosen for a reason specific to this disease. Treating a T-cell cancer is inherently difficult because the malignant cells resemble the healthy T cells the patient needs — a therapy killing T cells broadly causes profound immunosuppression.

KIR3DL2 is expressed on the malignant cells in this lymphoma and on very few normal cells, which allows the antibody to distinguish cancer from the healthy immune population. That selectivity is the whole reason a targeted approach is possible here.

Where it stands

Lacutamab is in a Phase 3 confirmatory trial, TELLOMAK-3, and has earned Fast Track and PRIME designations, with an accelerated-approval submission underway.

PRIME is the European Medicines Agency’s equivalent priority scheme, and holding both suggests regulators on either side of the Atlantic have accepted the unmet need argument.

Running a confirmatory trial while an accelerated-approval submission proceeds is the standard sequence — the drug can reach patients on earlier evidence while the definitive study generates the data required to keep it there.

The deal structure, and who it suits

Sobi gains exclusive global commercialisation rights upon accelerated approval and worldwide development rights if the Phase 3 succeeds; Innate remains the developer.

That division solves a specific problem for a company like Innate. It has produced a first-in-class antibody through late-stage development — genuinely difficult scientific work — and has no commercial infrastructure to sell it. Building one for a rare cancer means recruiting a sales organisation to reach a small number of specialist centres, which is expensive and would consume the capital the company uses for research.

“A pivotal moment” for entering the oncology market, said Innate CEO Jonathan Dickinson — and the arrangement lets the company remain what it is good at being while someone else handles the route to patients.

Why Sobi is the counterparty

Sobi specialises in rare disease, which is a distinct commercial capability rather than a general one.

Selling into rare disease means identifying scattered patients through registries and referral networks, engaging a small number of expert physicians who treat most cases, and negotiating reimbursement for high-priced therapies where payers scrutinise each case individually. A company that already does that across other rare conditions can add an oncology product without building anything new.

The staged rights transfer

Sobi gaining commercialisation rights on accelerated approval and worldwide development rights only if Phase 3 succeeds is a carefully graded structure.

It means Sobi commits progressively as risk falls: taking on commercialisation once regulators have accepted the drug is approvable, and assuming development responsibility only after the confirmatory trial removes the possibility of withdrawal.

How cutaneous lymphoma is treated now

Understanding the current options clarifies what a targeted antibody would add.

Early-stage mycosis fungoides is managed with skin-directed therapy — topical steroids, light therapy, localised radiation — which controls disease for years in many patients without systemic treatment. That works reasonably and is not the unmet need.

Advanced disease and Sézary syndrome are different. Systemic options include retinoids, interferon, methotrexate, a histone deacetylase inhibitor, an antibody-drug conjugate targeting CD30 and, for eligible patients, a photopheresis procedure treating circulating cells outside the body. Responses are frequently partial and rarely durable.

Allogeneic stem cell transplant is potentially curative and available to few, given the age and condition of most patients.

Symptom burden also drives the need in a way survival statistics do not capture. The itching in Sézary syndrome is described by patients as the dominant feature of their illness, unresponsive to conventional treatment and severely disruptive to sleep and daily function — so a therapy reducing disease burden matters to quality of life immediately, independent of whether it extends survival.

For Innate, that means retaining development control — and the associated cost — through the period of greatest uncertainty, with the upfront and near-term milestones funding it. The $75 million upfront against $465 million in later milestones reflects exactly that risk distribution. Business news, not investment advice.